ClinicalTrials.gg
CompletedNCT04126733Updated Jul 18, 2023Results posted

Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)

A Phase 2 interventional study of Regorafenib (Stivarga, BAY73-4506) and Nivolumab (Opdivo) in Colorectal Cancer, sponsored by Bayer. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-18.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing regorafenib in Colorectal Neoplasms — 10 open to participants now, 15 under way, 3 of them phase 3. regorafenib · Colorectal Neoplasms.

Enrollment
24th of 58
70 · median 55
Started
2019
with 6 others
Phase 2
29 of 59
5 open now
Registered
41st of 59
by date
Lead sponsor
10 of 59
Bayer

Among the 59 studies testing regorafenib in Colorectal Neoplasms, this one is the 24th largest by enrollment of the 58 interventional ones that give a count, is one of 7 that started in 2019, is one of 29 in phase 2, and was the 41st registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

10 of the 59 studies testing regorafenib in Colorectal Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About regorafenib

regorafenib: first FDA approval 2012 (STIVARGA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing regorafenib in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to learn if combination of the two drugs regorafenib and nivolumab is an effective treatment for pMMR - MSS colorectal cancer, a special type of cancer of the colon or rectum (pMMR stands for proficient Mismatch Repair; MSS stands for Microsatellite Stable) and whether it is safe for patients. Regorafenib works by blocking several different proteins involved in tumor growth. Nivolumab is an immunotherapy drug encouraging the body's own immune system to attack cancer cells.

Both drugs have been approved, but not for how they are being used as combination therapy in this study. Brand name of regorafenib is Stivarga; brand name of nivolumab is Opdivo.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological confirmed advanced, , or progressive pMMR/MSS adenocarcinoma of colon or rectum
  • Participant must have progressed or be intolerant to prior systemic chemotherapy including fluoropyrimidines, irinotecan, oxaliplatin, anti-vascular endothelial growth factor (VEGF) therapy, and, if extended rat sarcoma viral oncogene homolog (RAS) wild type, an anti-epidermal growth factor receptor (EGFR) therapy. Exceptions may apply
  • Participants must have adequate organ and marrow function defined by protocol-specified laboratory tests
  • (ECOG) performance status of 0 to 1
  • as determined by (RECIST) v1.1
  • Provision of recently obtained tumor tissue as per protocol specified requirement
  • Anticipated greater than 3 months
  • Be able to swallow and absorb oral tablets

Exclusion criteria

Exclusion Criteria:

  • Participants with Mismatch repair deficient (dMMR) / microsatellite instable-high (MSI-H) colorectal cancer
  • Prior therapy with regorafenib, anti-programmed cell death protein 1 (), programmed cell death protein 1 ligand 1 (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, or any form of immunotherapy to treat cancer
  • Presence of active central nervous system (CNS) ; participants with stable CNS disease or previously treated lesions are eligible for study entry
  • Poorly controlled hypertension, defined as a blood pressure consistently above 150/90 mmHg despite optimal medical management
  • Arterial thrombotic or embolic events such as cerebrovascular accident (including ) within 6 months before the start of study medication. Active pulmonary emboli or deep vein thrombosis that are significant or not adequately controlled on anticoagulation regimen
  • Any hemorrhage or bleeding event ≥ National Cancer Institute - (NCI-CTCAE) Grade 3 within 28 days prior to the start of study medication
  • Participants with an active, known or suspected disease
  • History of interstitial lung disease or pneumonitis
  • Known history of (HIV) infection or current chronic or active or C infection
  • Other protocol defined inclusion/exclusion criteria could apply
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Regorafenib + Nivolumab

    Drug: Regorafenib (Stivarga, BAY73-4506) · Biological: Nivolumab (Opdivo)

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 Assessed by Investigator

    ORR was defined as the percentage of participants with overall response of complete response (CR) or partial response (PR). CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have decreased in size to have a short axis of \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters.

    Time frame: Through database cut-off date of 11-NOV-2020 (Primary Completion Date) (up to 13 months)

Secondary outcomes

  1. Duration of Response (DOR)

    DOR was defined for responders only as the time from first documentation of response (i.e. CR or PR) until disease progression or death (if death without documented disease progression). CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have decreased in size to have a short axis of \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters.

    Time frame: Through last patient last visit (LPLV) at date of 28 MAR 2022 (up to 30 months)

  2. Disease Control Rate (DCR) at 8 and 16 Weeks

    DCR was defined as the percentage of participants with tumor response of complete response (CR), partial response (PR) or stable disease (SD). CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have decreased in size to have a short axis of \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study.

    Time frame: At 8, 16, 24, 32 and 40 weeks

  3. Progression-free Survival (PFS)

    PFS was the time from first dose of study medication to disease progression or death, whichever was earlier.

    Time frame: Through last patient last visit (LPLV) at date of 28 MAR 2022 (up to 30 months)

  4. Overall Survival (OS)

    OS was defined as time from first dose of the study treatment to death. For patients who did not die, OS was censored at the last time point at which the survival status was known to be alive.

    Time frame: Through last patient last visit (LPLV) at date of 28 MAR 2022 (up to 30 months)

  5. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Different Severity Types of TEAEs Per Common Terminology Criteria for Adverse Events (CTCAE) v5

    TEAEs were started during treatment or within the post-treatment time window (30 days after last dose of regorafenib and 100 days after last dose of nivolumab.). TEAEs were summarized by system organ class (SOC) and preferred term, severity (based on CTCAE v5 grades). Laboratory data considered as AE were graded according to CTCAE v5. Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.

    Time frame: 30 days after last dose of regorafenib and 100 days after last dose of nivolumab until study completion (up to 30 months)

07

Results

Posted Dec 14, 2021
Limitations and caveats
Preliminary efficacy assessment suggested that the study would not meet its primary efficacy endpoint, therefore the study was stopped.

Participant flow

Study was conducted at 12 centers (of which at least one participant was treated) in the United States between 14-OCT-2019 (first participant first visit) and 28-MAR-2022 (last participant last visit).

Treatment Period
Participant flow — Treatment Period
MilestoneRegorafenib Plus Nivolumab
Started70
Completed0
Not completed70
Withdrew: Progressive disease - radiological progression47
Withdrew: Adverse event8
Withdrew: Progressive disease - clinical assessment7
Withdrew: Physician decision5
Withdrew: Death1
Withdrew: Other reasons2
Active Follow-up Period
Participant flow — Active Follow-up Period
MilestoneRegorafenib Plus Nivolumab
Started39
Completed19
Not completed20
Withdrew: Death13
Withdrew: Progressive disease - clinical assessment4
Withdrew: Withdrawal by subject2
Withdrew: Other reasons1
Long-term Follow-up Period
Participant flow — Long-term Follow-up Period
MilestoneRegorafenib Plus Nivolumab
Started29
Completed0
Not completed29
Withdrew: Death22
Withdrew: Withdrawal by subject1
Withdrew: Ongoing with long term follow-up6

Outcome measures

PrimaryOverall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 Assessed by Investigator

ORR was defined as the percentage of participants with overall response of complete response (CR) or partial response (PR). CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have decreased in size to have a short axis of \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters.

Time frame:
Through database cut-off date of 11-NOV-2020 (Primary Completion Date) (up to 13 months)
Reported as:
Number · percentage (%) of participants
Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 Assessed by Investigator
percentage (%) of participantsRegorafenib Plus Nivolumab
Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 Assessed by Investigator7.1 (2.4 to 15.9)
Statistical analysis
  • Regorafenib Plus Nivolumab · Exact Binomial Test · p = 0.2721 (The target response rate for the combination treatment was 17%. Using a one-sided exact binomial test at a type-I error of at most 2.5% at least 8 responders out of the 70 patients were needed to achieve significance.) · Rate: 7.1 · 95% CI 2.4 to 15.9
SecondaryDuration of Response (DOR)

DOR was defined for responders only as the time from first documentation of response (i.e. CR or PR) until disease progression or death (if death without documented disease progression). CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have decreased in size to have a short axis of \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters.

Time frame:
Through last patient last visit (LPLV) at date of 28 MAR 2022 (up to 30 months)
Reported as:
Median · weeks
Duration of Response (DOR)
weeksRegorafenib Plus Nivolumab
Duration of Response (DOR)NA (16.14 to NA)
SecondaryDisease Control Rate (DCR) at 8 and 16 Weeks

DCR was defined as the percentage of participants with tumor response of complete response (CR), partial response (PR) or stable disease (SD). CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have decreased in size to have a short axis of \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study.

Time frame:
At 8, 16, 24, 32 and 40 weeks
Reported as:
Number · percentage (%) of participants
Disease Control Rate (DCR) at 8 and 16 Weeks
percentage (%) of participantsRegorafenib Plus Nivolumab
Disease Control Rate at 8 weeks38.6 (27.2 to 51.0)
Disease Control Rate at 16 weeks38.6 (27.2 to 51.0)
Disease Control Rate at 24 weeks38.6 (27.2 to 51.0)
Disease Control Rate at 32 weeks38.6 (27.2 to 51.0)
Disease Control Rate at 40 weeks38.6 (27.2 to 51.0)
SecondaryProgression-free Survival (PFS)

PFS was the time from first dose of study medication to disease progression or death, whichever was earlier.

Time frame:
Through last patient last visit (LPLV) at date of 28 MAR 2022 (up to 30 months)
Reported as:
Median · weeks
Progression-free Survival (PFS)
weeksRegorafenib Plus Nivolumab
Progression-free Survival (PFS)8.00 (7.86 to 10.57)
SecondaryOverall Survival (OS)

OS was defined as time from first dose of the study treatment to death. For patients who did not die, OS was censored at the last time point at which the survival status was known to be alive.

Time frame:
Through last patient last visit (LPLV) at date of 28 MAR 2022 (up to 30 months)
Reported as:
Median · weeks
Overall Survival (OS)
weeksRegorafenib Plus Nivolumab
Overall Survival (OS)51.86 (30.29 to 69.71)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Different Severity Types of TEAEs Per Common Terminology Criteria for Adverse Events (CTCAE) v5

TEAEs were started during treatment or within the post-treatment time window (30 days after last dose of regorafenib and 100 days after last dose of nivolumab.). TEAEs were summarized by system organ class (SOC) and preferred term, severity (based on CTCAE v5 grades). Laboratory data considered as AE were graded according to CTCAE v5. Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.

Time frame:
30 days after last dose of regorafenib and 100 days after last dose of nivolumab until study completion (up to 30 months)
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Different Severity Types of TEAEs Per Common Terminology Criteria for Adverse Events (CTCAE) v5
participantsRegorafenib Plus Nivolumab
Any AEs69
Serious AEs34
Worst grade: Grade 13
Worst grade: Grade 218
Worst grade: Grade 338
Worst grade: Grade 47
Worst grade: Grade 5 (death)3
Worst grade: Grade 1 or 221
Worst grade: Grade 3 or 445
Worst grade: Grade 3, 4, or 548
Grade 5 (death) between Day X+1 and Day 303
Grade 5 (death) between Day 31 and Day 1000
Post-hocDuration of Stable Disease

Duration of stable disease was measured from the start of the treatment until the criteria for progression were met.

Time frame:
Through last patient last visit (LPLV) at date of 28 MAR 2022 (up to 30 months)
Reported as:
Median · weeks
Duration of Stable Disease
weeksRegorafenib Plus Nivolumab
Duration of Stable Disease29.86 (15.86 to 32.00)

Adverse events

Collected over An adverse event (AE) was considered as treatment-emergent (TEAE) if it started during treatment or within the post-treatment time window (30 days after last dose of regorafenib and 100 days after last dose of nivolumab) until study completion (up to 30 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Regorafenib Plus Nivolumab40/70 (57.1%)34/70 (48.6%)66/70 (94.3%)
Most frequent serious events
Showing 10 of 132
Most frequent serious events
EventRegorafenib Plus Nivolumab
PneumoniaInfections and infestations5/70
PyrexiaGeneral disorders4/70
PneumoniaInfections and infestations4/70
SepsisInfections and infestations4/70
PyrexiaGeneral disorders4/70
PneumoniaInfections and infestations4/70
SepsisInfections and infestations4/70
PyrexiaGeneral disorders4/70
SepsisInfections and infestations4/70
HyponatraemiaMetabolism and nutrition disorders3/70
Most frequent other events
Showing 10 of 165
Most frequent other events
EventRegorafenib Plus Nivolumab
FatigueGeneral disorders30/70
FatigueGeneral disorders30/70
FatigueGeneral disorders30/70
Decreased appetiteMetabolism and nutrition disorders21/70
Decreased appetiteMetabolism and nutrition disorders21/70
Decreased appetiteMetabolism and nutrition disorders21/70
Rash maculo-papularSkin and subcutaneous tissue disorders20/70
Rash maculo-papularSkin and subcutaneous tissue disorders20/70
Rash maculo-papularSkin and subcutaneous tissue disorders20/70
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders19/70

Baseline characteristics

Age, Continuous
Age, Continuous(years)Regorafenib Plus Nivolumab
Mean57.9 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)Regorafenib Plus Nivolumab
Female29
Male41
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Regorafenib Plus Nivolumab
Hispanic or Latino7
Not Hispanic or Latino61
Unknown or Not Reported2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Regorafenib Plus Nivolumab
American Indian or Alaska Native0
Asian7
Native Hawaiian or Other Pacific Islander1
Black or African American10
White50
More than one raceNA
Unknown or Not Reported2
Baseline ECOG Performance Status
Baseline ECOG Performance Status(participants)Regorafenib Plus Nivolumab
0 - Fully Active36
1 - Restricted Activity34
08

Study locations

15 sites
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • Rocky Mountain Cancer Centers
    Denver, Colorado 80218, United States
  • Miami Cancer Institute at Baptist Health South Florida
    Miami, Florida 33176, United States
  • Illinois Cancer Specialists
    Arlington Heights, Illinois 60005, United States
  • Minnesota Oncology Hematology, PA
    Minneapolis, Minnesota 55404, United States
  • Nebraska Cancer Specialists
    Papillion, Nebraska 68046, United States
  • New York Oncology Hematology. P.C.
    Albany, New York 12206, United States
  • Willamette Valley Cancer Institute and Research Center
    Eugene, Oregon 97401, United States
  • Sarah Cannon Cancer Center
    Nashville, Tennessee 37203, United States
  • Texas Oncology-Arlington North
    Arlington, Texas 76012, United States
  • Baylor Charles A. Sammons Cancer Center at Dallas
    Dallas, Texas 75246, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Texas Oncology-Sherman
    Sherman, Texas 75090, United States
  • Virginia Oncology Associates
    Newport News, Virginia 23606, United States
  • Northwest Cancer Specialists, PC
    Vancouver, Washington 98684, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Nov 2020, 12 months.

Results were first posted in Dec 2021, 1 year 1 month after primary completion.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 12 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2019
First posted
Oct 15, 2019
StartActual
Oct 14, 2019
Primary completionActual
Nov 11, 2020
CompletionActual
Mar 28, 2022
Results first posted
Dec 14, 2021
Last update
Jul 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04126733
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Oct 15, 2019
Start date
Oct 14, 2019
Primary completion
Nov 11, 2020
Completion
Mar 28, 2022
Results posted
Dec 14, 2021
Last update
Jul 18, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Regorafenib · Nivolumab

Start the discussion